Skip to main content
Erschienen in: Die Dermatologie 7/2022

10.06.2022 | Atopische Dermatitis | Leitthema

Pruritus bei atopischer Dermatitis – vergleichende Bewertung neuer Therapieansätze

verfasst von: Dr. med. Svenja Müller, Felix Witte, Sonja Ständer

Erschienen in: Die Dermatologie | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Chronischer Pruritus (Dauer ≥ 6 Wochen) betrifft ca. 91 % der Patienten mit atopischer Dermatitis (AD). Neben reinem Jucken werden häufig Begleitsensationen wie Schmerzen, Brennen, Stechen und Hitzegefühl berichtet. Der Leidensdruck betroffener Patienten ist dadurch hoch; Schlaf und Lebensqualität können stark beeinträchtigt sein. Im Fokus der Behandlung der AD steht daher auch die suffiziente Kontrolle des Pruritus. Neben einer intensiven rückfettenden Basispflege können topisch Kortikosteroide und Calcineurininhibitoren angewendet werden. Bei ausgeprägtem Hautbefund kann Phototherapie zur Abheilung von Ekzemen und Linderung des atopischen Pruritus beitragen. Im Hinblick auf Systemtherapien stehen mehrere zugelassene Biologika (Dupilumab, Tralokinumab) und Januskinase-Inhibitoren (Baricitinib, Upadacitinib, Abrocitinib) zur Verfügung, die über die Interferenz mit der Signaltransduktion proinflammatorischer Zytokine zu einer raschen Pruritusreduktion führen. Während Januskinase-Inhibitoren zu einer initial schnelleren Prurituslinderung führen, scheinen sich Biologika und Januskinase-Inhibitoren mit zunehmender Therapiedauer hinsichtlich ihrer antipruritischen Wirksamkeit anzugleichen.
Literatur
1.
Zurück zum Zitat Agache I, Song Y, Posso M et al (2021) Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 76(1):45–58 PubMedCrossRef Agache I, Song Y, Posso M et al (2021) Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 76(1):45–58 PubMedCrossRef
2.
Zurück zum Zitat Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z et al (2013) Oral H1 antihistamines as monotherapy for eczema. Cochrane Database Syst Rev 2:CD7770 Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z et al (2013) Oral H1 antihistamines as monotherapy for eczema. Cochrane Database Syst Rev 2:CD7770
4.
Zurück zum Zitat Bergasa NV, Talbot TL, Alling DW et al (1992) A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102(2):544–549 PubMedCrossRef Bergasa NV, Talbot TL, Alling DW et al (1992) A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102(2):544–549 PubMedCrossRef
5.
Zurück zum Zitat Bieber T (2022) Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 21(1):21–40 PubMedCrossRef Bieber T (2022) Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 21(1):21–40 PubMedCrossRef
6.
Zurück zum Zitat Bieber T, Simpson EL, Silverberg JI et al (2021) Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 384(12):1101–1112 PubMedCrossRef Bieber T, Simpson EL, Silverberg JI et al (2021) Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 384(12):1101–1112 PubMedCrossRef
7.
Zurück zum Zitat Blauvelt A, Teixeira HD, Simpson EL et al (2021) Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 157(9):1047–1055 PubMedPubMedCentralCrossRef Blauvelt A, Teixeira HD, Simpson EL et al (2021) Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 157(9):1047–1055 PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat de Bruin-Weller M, Pink AE, Patrizi A et al (2021) Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat 32(2):164–173 PubMedCrossRef de Bruin-Weller M, Pink AE, Patrizi A et al (2021) Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat 32(2):164–173 PubMedCrossRef
9.
Zurück zum Zitat Cork MJ, Eckert L, Simpson EL et al (2020) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat 31(6):606–614 PubMedCrossRef Cork MJ, Eckert L, Simpson EL et al (2020) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat 31(6):606–614 PubMedCrossRef
10.
Zurück zum Zitat Dawn A, Papoiu ADP, Chan YH et al (2009) Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 160(3):642–644 PubMedCrossRef Dawn A, Papoiu ADP, Chan YH et al (2009) Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 160(3):642–644 PubMedCrossRef
11.
Zurück zum Zitat Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Küster D, Siegels D, Schmitt J, Flohr C (2020) Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. JAMA Dermatol 156(6):659–667 PubMedCrossRef Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Küster D, Siegels D, Schmitt J, Flohr C (2020) Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. JAMA Dermatol 156(6):659–667 PubMedCrossRef
12.
Zurück zum Zitat Ekelem C, Juhasz M, Khera P, Mesinkovska NA (2019) Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review. JAMA Dermatol 155(2):229–236 PubMedCrossRef Ekelem C, Juhasz M, Khera P, Mesinkovska NA (2019) Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review. JAMA Dermatol 155(2):229–236 PubMedCrossRef
13.
Zurück zum Zitat Garritsen FM, Brouwer MWD, Limpens J et al (2014) Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 170(3):501–513 PubMedCrossRef Garritsen FM, Brouwer MWD, Limpens J et al (2014) Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 170(3):501–513 PubMedCrossRef
14.
15.
Zurück zum Zitat Guttman-Yassky E, Teixeira HD, Simpson EL et al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397(10290):2151–2168 PubMedCrossRef Guttman-Yassky E, Teixeira HD, Simpson EL et al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397(10290):2151–2168 PubMedCrossRef
16.
Zurück zum Zitat Haeck IM, Knol MJ, Ten Berge O et al (2011) Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 64(6):1074–1084 PubMedCrossRef Haeck IM, Knol MJ, Ten Berge O et al (2011) Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 64(6):1074–1084 PubMedCrossRef
17.
Zurück zum Zitat Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 92:44–47 Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 92:44–47
18.
Zurück zum Zitat Huet F, Faffa M‑S, Poizeau F et al (2019) Characteristics of pruritus in relation to self-assessed severity of atopic dermatitis. Acta Derm Venereol 99(3):279–283 PubMedCrossRef Huet F, Faffa M‑S, Poizeau F et al (2019) Characteristics of pruritus in relation to self-assessed severity of atopic dermatitis. Acta Derm Venereol 99(3):279–283 PubMedCrossRef
19.
Zurück zum Zitat Hundley JL, Yosipovitch G (2004) Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 50(6):889–891 PubMedCrossRef Hundley JL, Yosipovitch G (2004) Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 50(6):889–891 PubMedCrossRef
20.
Zurück zum Zitat Klein B, Treudler R, Simon JC (2022) JAK-inhibitors in dermatology—small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges 20(1):19–24 PubMed Klein B, Treudler R, Simon JC (2022) JAK-inhibitors in dermatology—small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges 20(1):19–24 PubMed
21.
Zurück zum Zitat Legat FJ (2021) Itch in atopic dermatitis—what is new? Front Med (Lausanne) 8:644760 CrossRef Legat FJ (2021) Itch in atopic dermatitis—what is new? Front Med (Lausanne) 8:644760 CrossRef
22.
Zurück zum Zitat Malekzad F, Arbabi M, Mohtasham N et al (2009) Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 23(8):948–950 PubMedCrossRef Malekzad F, Arbabi M, Mohtasham N et al (2009) Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 23(8):948–950 PubMedCrossRef
23.
Zurück zum Zitat Matsuda KM, Sharma D, Schonfeld AR et al (2016) Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol 75(3):619–625 PubMedCrossRef Matsuda KM, Sharma D, Schonfeld AR et al (2016) Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol 75(3):619–625 PubMedCrossRef
24.
Zurück zum Zitat Matterne U, Böhmer MM, Weisshaar E et al (2019) Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 1:CD12167 PubMed Matterne U, Böhmer MM, Weisshaar E et al (2019) Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 1:CD12167 PubMed
25.
Zurück zum Zitat Misery L, Belloni Fortina A, El Hachem M et al (2021) A position paper on the management of itch and pain in atopic dermatitis from the international society of atopic dermatitis (ISAD)/oriented patient-education network in dermatology (OPENED) task force. J Eur Acad Dermatol Venereol 35(4):787–796 PubMedCrossRef Misery L, Belloni Fortina A, El Hachem M et al (2021) A position paper on the management of itch and pain in atopic dermatitis from the international society of atopic dermatitis (ISAD)/oriented patient-education network in dermatology (OPENED) task force. J Eur Acad Dermatol Venereol 35(4):787–796 PubMedCrossRef
26.
Zurück zum Zitat Monroe EW (1989) Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 21(1):135–136 PubMedCrossRef Monroe EW (1989) Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 21(1):135–136 PubMedCrossRef
27.
Zurück zum Zitat Paller AS, Bansal A, Simpson EL et al (2020) Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 21(1):119–131 PubMedCrossRef Paller AS, Bansal A, Simpson EL et al (2020) Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 21(1):119–131 PubMedCrossRef
28.
Zurück zum Zitat Patruno C, Napolitano M, Argenziano G et al (2021) Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35(4):958–964 PubMedCrossRef Patruno C, Napolitano M, Argenziano G et al (2021) Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35(4):958–964 PubMedCrossRef
29.
Zurück zum Zitat Patruno C, Fabbrocini G, Longo G et al (2021) Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 22(4):581–586 PubMedCrossRef Patruno C, Fabbrocini G, Longo G et al (2021) Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 22(4):581–586 PubMedCrossRef
30.
Zurück zum Zitat Pavlis J, Yosipovitch G (2018) Management of itch in atopic dermatitis. Am J Clin Dermatol 19(3):319–332 PubMedCrossRef Pavlis J, Yosipovitch G (2018) Management of itch in atopic dermatitis. Am J Clin Dermatol 19(3):319–332 PubMedCrossRef
31.
Zurück zum Zitat Pereira MP, Zeidler C, Ständer S (2021) Improvement of chronic kidney disease-associated pruritus after treatment with intravenous naloxone. JAMA Dermatol 157(11):1380–1381 PubMedCrossRef Pereira MP, Zeidler C, Ständer S (2021) Improvement of chronic kidney disease-associated pruritus after treatment with intravenous naloxone. JAMA Dermatol 157(11):1380–1381 PubMedCrossRef
32.
Zurück zum Zitat Puar N, Chovatiya R, Paller AS (2021) New treatments in atopic dermatitis. Ann Allergy Asthma Immunol 126(1):21–31 PubMedCrossRef Puar N, Chovatiya R, Paller AS (2021) New treatments in atopic dermatitis. Ann Allergy Asthma Immunol 126(1):21–31 PubMedCrossRef
34.
Zurück zum Zitat Reich K, Kabashima K, Peris K et al (2020) Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(12):1333–1343 PubMedCrossRef Reich K, Kabashima K, Peris K et al (2020) Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(12):1333–1343 PubMedCrossRef
35.
Zurück zum Zitat Reich K, Teixeira HD, de Bruin-Weller M et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397(10290):2169–2181 PubMedCrossRef Reich K, Teixeira HD, de Bruin-Weller M et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397(10290):2169–2181 PubMedCrossRef
36.
Zurück zum Zitat Reynolds NJ, Franklin V, Gray JC et al (2001) Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 357(9273):2012–2016 PubMedCrossRef Reynolds NJ, Franklin V, Gray JC et al (2001) Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 357(9273):2012–2016 PubMedCrossRef
37.
Zurück zum Zitat Ring J, Abraham A, de Cuyper C et al (2008) Control of atopic eczema with pimecrolimus cream 1 % under daily practice conditions: results of a 2000 patient study. J Eur Acad Dermatol Venereol 22(2):195–203 PubMedCrossRef Ring J, Abraham A, de Cuyper C et al (2008) Control of atopic eczema with pimecrolimus cream 1 % under daily practice conditions: results of a 2000 patient study. J Eur Acad Dermatol Venereol 22(2):195–203 PubMedCrossRef
38.
Zurück zum Zitat Schram ME, Roekevisch E, Leeflang MMG et al (2011) A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 128(2):353–359 PubMedCrossRef Schram ME, Roekevisch E, Leeflang MMG et al (2011) A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 128(2):353–359 PubMedCrossRef
39.
Zurück zum Zitat Silverberg JI, Simpson EL, Thyssen JP et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(8):863–873 PubMedCrossRef Silverberg JI, Simpson EL, Thyssen JP et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(8):863–873 PubMedCrossRef
40.
Zurück zum Zitat Silverberg JI, Thyssen JP, Simpson EL et al (2021) Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol 22(4):541–554 PubMedPubMedCentralCrossRef Silverberg JI, Thyssen JP, Simpson EL et al (2021) Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol 22(4):541–554 PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Silverberg JI, Toth D, Bieber T et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184(3):450–463 PubMedPubMedCentralCrossRef Silverberg JI, Toth D, Bieber T et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184(3):450–463 PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M (2021) Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 35(9):1797–1810 PubMedPubMedCentralCrossRef Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M (2021) Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 35(9):1797–1810 PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Simpson EL, Gadkari A, Worm M et al (2016) Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PRos): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 75(3):506–515 PubMedCrossRef Simpson EL, Gadkari A, Worm M et al (2016) Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PRos): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 75(3):506–515 PubMedCrossRef
44.
Zurück zum Zitat Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348 PubMedCrossRef Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348 PubMedCrossRef
45.
Zurück zum Zitat Simpson EL, Lacour J‑P, Spelman L et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183(2):242–255 PubMedCrossRef Simpson EL, Lacour J‑P, Spelman L et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183(2):242–255 PubMedCrossRef
46.
Zurück zum Zitat Simpson EL, Wollenberg A, Bissonnette R et al (2021) Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib. Dermatitis 32(1S):S53–S61 PubMedCrossRef Simpson EL, Wollenberg A, Bissonnette R et al (2021) Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib. Dermatitis 32(1S):S53–S61 PubMedCrossRef
48.
Zurück zum Zitat Ständer S, Böckenholt B, Schürmeyer-Horst F et al (2009) Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 89(1):45–51 PubMedCrossRef Ständer S, Böckenholt B, Schürmeyer-Horst F et al (2009) Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 89(1):45–51 PubMedCrossRef
49.
Zurück zum Zitat Vakharia PP, Cella D, Silverberg JI (2018) Patient-reported outcomes and quality of life measures in atopic dermatitis. Clin Dermatol 36(5):616–630 PubMedCrossRef Vakharia PP, Cella D, Silverberg JI (2018) Patient-reported outcomes and quality of life measures in atopic dermatitis. Clin Dermatol 36(5):616–630 PubMedCrossRef
50.
Zurück zum Zitat van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z et al (2014) No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev 3:25 PubMedPubMedCentralCrossRef van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z et al (2014) No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev 3:25 PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Weisshaar E (2020) Antihistaminika bei Pruritus : Das Ende einer Ära? Hautarzt 71(7):525–527 PubMedCrossRef Weisshaar E (2020) Antihistaminika bei Pruritus : Das Ende einer Ära? Hautarzt 71(7):525–527 PubMedCrossRef
52.
Zurück zum Zitat Wollenberg A, Barbarot S, Bieber T et al (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 32(5):657–682 PubMedCrossRef Wollenberg A, Barbarot S, Bieber T et al (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 32(5):657–682 PubMedCrossRef
53.
Zurück zum Zitat Wollenberg A, Blauvelt A, Guttman-Yassky E et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437–449 PubMedCrossRef Wollenberg A, Blauvelt A, Guttman-Yassky E et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437–449 PubMedCrossRef
54.
Zurück zum Zitat Wollenberg A, Weidinger S, Worm M et al (2021) Tralokinumab in atopic dermatitis. J Dtsch Dermatol Ges 19(10):1435–1442 PubMed Wollenberg A, Weidinger S, Worm M et al (2021) Tralokinumab in atopic dermatitis. J Dtsch Dermatol Ges 19(10):1435–1442 PubMed
55.
Zurück zum Zitat Yosipovitch G, Misery L, Proksch E et al (2019) Skin barrier damage and itch: review of mechanisms, topical management and future directions. Acta Derm Venereol 99(13):1201–1209 PubMedCrossRef Yosipovitch G, Misery L, Proksch E et al (2019) Skin barrier damage and itch: review of mechanisms, topical management and future directions. Acta Derm Venereol 99(13):1201–1209 PubMedCrossRef
Metadaten
Titel
Pruritus bei atopischer Dermatitis – vergleichende Bewertung neuer Therapieansätze
verfasst von
Dr. med. Svenja Müller
Felix Witte
Sonja Ständer
Publikationsdatum
10.06.2022
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 7/2022
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-022-05011-7

Weitere Artikel der Ausgabe 7/2022

Die Dermatologie 7/2022 Zur Ausgabe

Wie lautet Ihre Diagnose?

Unklarer Knoten am Hals

Passend zum Thema

Screen Laserbootcamp
ANZEIGE

26.01.2022 | Online-Artikel

Experten-Talk „Bepanthen® Laserbootcamp – Grundlagen, Anwendung, Stellenwert"

Beim „Bepanthen® Laserbootcamp“ beleuchten drei Dermatologie-Experten die Grundlagen der Lasertherapie in der Praxis, neueste Forschungsergebnisse und geben einen Ausblick auf die neue Leitlinie „Lasertherapie der Haut“. 

DDG Tagung Virtuell
ANZEIGE

24.05.2021 | Online-Artikel

Laser- und Strahlentherapie: Mit Dexpanthenol nachbehandeln

Laser- und Strahlentherapien können Haut- und Schleimhautschäden verursachen und entzündliche Prozesse auslösen. Die von Prof. Dr. Gerber, Düsseldorf, und Prof. Dr. Baron, Aachen, auf der 51. DDG-Jahrestagung präsentierten aktuellen Daten zeigen, dass Dexpanthenol-haltige Topika (z.B. Bepanthen® Wund- und Heilsalbe) den Heilungsprozess und die Regeneration der geschädigten Haut bzw. Schleimhaut beschleunigen.

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.